Oncolytic viruses (OVs) is a group of viruses that selectively replicate in and kill cancer cells, while leaving the normal tissue uninfected. In addition to direct oncolysis activity, OVs are also very effective at inducing immune responses against tumor cells. OVs encompass a broad diversity of DNA and RNA viruses that are naturally cancer-selective or can be genetically-engineered. OVs provide a diverse platform for immunotherapy; they act as in situ vaccines, and can be armed with immuno-modulatory transgenes or combined with other immunotherapies, such as immune-checkpoint inhibitor, engineered T cell (CAR-T, TCR-T, etc), bi-specific antibody or chemotherapies. Taking advantage of the OncoVirapy™ platform, Creative Biolabs provides customized, standardized, reliable and high-quality oncolytic virus therapy development services for clients globally. Our service covers all aspects from virus engineering, cell biology to animal testing with a special emphasis on virus engineering and in vitro and in vivo validation.
To study the oncolytic efficacy and safety of oncolytic virus, scientists in Creative Biolabs have developed a comprehensive set of in vitro and in vivo assays. Since oncolytic virus is a kind of gene therapeutic product designed to be replication-competent, there are specific technical challenges for its characterization. To develop the assays for validation of this special agents, various aspects have been taken into consideration, such as selectivity, molecular variants, anti-tumor efficacy, immune system response, pharmacology, viral shedding, biodistribution, toxicology and safety. Specifically, with regard to selection of animal models, it’s essential to take into consideration the study purpose as well as the viral tropism, infectivity, replication ability, cytopathic potential, and anti-tumor effect. Both non-tumor-bearing animal species and tumor-bearing xenograft, syngeneic animal models or immunity-humanized animal models are useful for non-clinical testing.
To study the oncolytic efficacy and safety of oncolytic virus, scientists in Creative Biolabs has developed a comprehensive set of in vitro and in vivo assays. Since oncolytic virus is a kind of gene therapeutic product which is designed to be replication-competent, there are specific technical challenges for its characterization.
Please feel free to contact us for a quote and further discussion with our scientists.